{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Administration+of+Lotemax",
    "query": {
      "intervention": "Administration of Lotemax"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 25,
    "total_pages": 3,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Administration+of+Lotemax&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-11T10:14:35.062Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04708821",
      "title": "DEXTENZA Therapy for Treatment of Allergic Conjunctivitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Bilateral Conjunctivitis (Disorder)"
      ],
      "interventions": [
        {
          "name": "Dexamethasone ophthalmic insert 0.4Mg",
          "type": "DRUG"
        },
        {
          "name": "0.2% loteprednol etabonate ophthalmic suspension",
          "type": "DRUG"
        },
        {
          "name": "olopatadine hydrochloride ophthalmic solution 0.7%",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Clinical Research Center of Florida",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 31,
      "start_date": "2021-04-30",
      "completion_date": "2021-09-02",
      "has_results": false,
      "last_update_posted_date": "2022-04-13",
      "last_synced_at": "2026-09-11T10:14:35.062Z",
      "location_count": 1,
      "location_summary": "Pompano Beach, Florida",
      "locations": [
        {
          "city": "Pompano Beach",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04708821"
    },
    {
      "nct_id": "NCT00699153",
      "title": "Loteprednol Etabonate in an Ophthalmic Base vs Vehicle for the Treatment of Inflammation Following Cataract Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Ocular Inflammation"
      ],
      "interventions": [
        {
          "name": "Loteprednol Etabonate",
          "type": "DRUG"
        },
        {
          "name": "Vehicle of Ophthalmic Loteprednol Etabonate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bausch & Lomb Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 400,
      "start_date": "2008-06",
      "completion_date": "2009-06",
      "has_results": true,
      "last_update_posted_date": "2015-03-24",
      "last_synced_at": "2026-09-11T10:14:35.062Z",
      "location_count": 1,
      "location_summary": "High Point, North Carolina",
      "locations": [
        {
          "city": "High Point",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00699153"
    },
    {
      "nct_id": "NCT01456780",
      "title": "Efficacy of Zylet vs. Lotemax for the Treatment of Ocular Surface Inflammation/MGD/Blepharitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Meibomian Gland Dysfunction",
        "Posterior Blepharitis"
      ],
      "interventions": [
        {
          "name": "Loteprednol/tobramycin",
          "type": "DRUG"
        },
        {
          "name": "Loteprednol",
          "type": "DRUG"
        },
        {
          "name": "B+L Advanced Eye Relief Lubricant Drop",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts Eye and Ear Infirmary",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2011-08",
      "completion_date": "2017-06",
      "has_results": true,
      "last_update_posted_date": "2017-08-01",
      "last_synced_at": "2026-09-11T10:14:35.062Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01456780"
    },
    {
      "nct_id": "NCT05136443",
      "title": "Loteprednol Etabonate 0.25% for Prevention of Cornea Transplant Rejection",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Corneal Endothelial Dystrophy",
        "Corneal Edema"
      ],
      "interventions": [
        {
          "name": "loteprednol etabonate 0.25% ophthalmic suspension",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Price Vision Group",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 70,
      "start_date": "2021-11-23",
      "completion_date": "2023-09-05",
      "has_results": true,
      "last_update_posted_date": "2024-08-14",
      "last_synced_at": "2026-09-11T10:14:35.062Z",
      "location_count": 1,
      "location_summary": "Indianapolis, Indiana",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05136443"
    },
    {
      "nct_id": "NCT01996839",
      "title": "Loteprednol Ophthalmic Gel for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Inflammation",
        "Pain",
        "Cataract"
      ],
      "interventions": [
        {
          "name": "Loteprednol Etabonate Gel (BID)",
          "type": "DRUG"
        },
        {
          "name": "Loteprednol Etabonate Gel (TID)",
          "type": "DRUG"
        },
        {
          "name": "Vehicle (BID)",
          "type": "DRUG"
        },
        {
          "name": "Vehicle (TID)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bausch & Lomb Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 514,
      "start_date": "2013-12",
      "completion_date": "2014-07",
      "has_results": true,
      "last_update_posted_date": "2020-09-25",
      "last_synced_at": "2026-09-11T10:14:35.062Z",
      "location_count": 1,
      "location_summary": "Bridgewater, New Jersey",
      "locations": [
        {
          "city": "Bridgewater",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01996839"
    },
    {
      "nct_id": "NCT00560638",
      "title": "Loteprednol Etabonate Opthalmic Suspension for the Treatment of Dry Eye",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Dry Eye"
      ],
      "interventions": [
        {
          "name": "loteprednol etabonate ophthalmic suspension, 0.5%",
          "type": "DRUG"
        },
        {
          "name": "vehicle of loteprednol etabonate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bausch & Lomb Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 119,
      "start_date": "2005-11",
      "completion_date": "2006-02",
      "has_results": false,
      "last_update_posted_date": "2011-07-18",
      "last_synced_at": "2026-09-11T10:14:35.062Z",
      "location_count": 1,
      "location_summary": "Andover, Massachusetts",
      "locations": [
        {
          "city": "Andover",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00560638"
    },
    {
      "nct_id": "NCT01475643",
      "title": "Loteprednol vs Prednisolone for the Treatment of Intraocular Inflammation Following Cataract Surgery in Children.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Cataract"
      ],
      "interventions": [
        {
          "name": "Loteprednol etabonate",
          "type": "DRUG"
        },
        {
          "name": "Prednisolones acetate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bausch & Lomb Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "11 Years",
        "sex": "ALL",
        "summary": "Up to 11 Years"
      },
      "enrollment_count": 107,
      "start_date": "2013-06",
      "completion_date": "2017-07",
      "has_results": true,
      "last_update_posted_date": "2019-06-11",
      "last_synced_at": "2026-09-11T10:14:35.062Z",
      "location_count": 1,
      "location_summary": "Rochester, New York",
      "locations": [
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01475643"
    },
    {
      "nct_id": "NCT05322148",
      "title": "Cyclosporine 0.1% / Loteprednol 0.2% Effect on Anterior Segment Normalization",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Dry Eye"
      ],
      "interventions": [
        {
          "name": "Klarity CL, Cylcosporine 0.1%/Loteprednol Etabonate 0.2% Preservative Free",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Research Insight LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 59,
      "start_date": "2022-06-03",
      "completion_date": "2022-11-21",
      "has_results": false,
      "last_update_posted_date": "2023-01-04",
      "last_synced_at": "2026-09-11T10:14:35.062Z",
      "location_count": 3,
      "location_summary": "Hemet, California • Laguna Hills, California • Brecksville, Ohio",
      "locations": [
        {
          "city": "Hemet",
          "state": "California"
        },
        {
          "city": "Laguna Hills",
          "state": "California"
        },
        {
          "city": "Brecksville",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05322148"
    },
    {
      "nct_id": "NCT00420628",
      "title": "Pediatric Zylet Safety and Efficacy Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Chalazion",
        "Hordeolum"
      ],
      "interventions": [
        {
          "name": "loteprednol etabonate/tobramycin opthalmic suspension",
          "type": "DRUG"
        },
        {
          "name": "vehicle",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bausch & Lomb Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "6 Years",
        "sex": "ALL",
        "summary": "Up to 6 Years"
      },
      "enrollment_count": 108,
      "start_date": "2006-11",
      "completion_date": "2009-06",
      "has_results": true,
      "last_update_posted_date": "2011-10-07",
      "last_synced_at": "2026-09-11T10:14:35.062Z",
      "location_count": 1,
      "location_summary": "Erie, Pennsylvania",
      "locations": [
        {
          "city": "Erie",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00420628"
    },
    {
      "nct_id": "NCT04555694",
      "title": "Comparing Treatment of Dry Eye With Intracanalicular Dexamethasone, Restasis, and/or Lotemax",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Dry Eye"
      ],
      "interventions": [
        {
          "name": "Cyclosporine",
          "type": "DRUG"
        },
        {
          "name": "Loteprednol Etabonate",
          "type": "DRUG"
        },
        {
          "name": "Dexamethasone Ophthalmic 0.4 Mg Ophthalmic Insert",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Thomas Chester, OD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2020-10-01",
      "completion_date": "2022-02-16",
      "has_results": true,
      "last_update_posted_date": "2023-10-11",
      "last_synced_at": "2026-09-11T10:14:35.062Z",
      "location_count": 1,
      "location_summary": "Brecksville, Ohio",
      "locations": [
        {
          "city": "Brecksville",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04555694"
    }
  ]
}